Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.
Christian U. Blank, Minke W. Lucas, Richard A. Scolyer, Bart A. van de Wiel, Alexander M. Menzies, Marta López‐Yurda, Alexander Christopher Jonathan Van Akkooi, Winan J. van Houdt, Robyn P.M. Saw, Alex Torres Acosta, Serigne Lo, Geke A.P. Hospers, Matteo S. Carlino, Jan Willem de Groot, Ellen Kapiteijn, Karijn P.M. Suijkerbuijk, Piotr Rutkowski, Shahneen Sandhu, Astrid Aplonia Maria Van Der Veldt, Georgina V. Long (2024). Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.. , 42(17_suppl), DOI: https://doi.org/10.1200/jco.2024.42.17_suppl.lba2.
